New York, May 29, 2026, 14:02 EDT
- vTv Therapeutics slipped in Friday afternoon trading, trailing both of the biotechnology ETFs.
- The most recent update from the company is still its first-quarter report from May 13. In that report, it said enrollment for Phase 3 CATT1 should stay on track for the third quarter.
- The stock’s next hurdle is still in the clinic. Cadisegliatin doesn’t have approval, and both safety and efficacy are still not proven.
vTv Therapeutics Inc. shares fell 1.1% to $33.14 Friday afternoon, lagging behind a stronger biotech market with investors waiting on further news from its diabetes program. The SPDR S&P Biotech ETF gained around 0.8%, and the iShares Nasdaq Biotechnology ETF was up 0.2%.
vTv shares are trading now mostly on prospects for cadisegliatin, its oral candidate being trialed as an add-on to insulin in type 1 diabetes. The company said in a May 13 update that it still expects to finish enrolling its Phase 3 CATT1 study in the third quarter of 2026.
Nasdaq made the change in a normal U.S. session. The 2026 schedule put out by Nasdaq says markets shut for Memorial Day on May 25. The next full close is June 19 for Juneteenth.
vTv hasn’t posted any new filings or press releases in the last two days. Its investor page still lists May 13 filings and the first-quarter results as the most recent updates.
vTv said cash and cash equivalents totaled $98.1 million at March 31, up from $88.9 million at the end of last year. The increase came after a $20 million upfront payment from the amended Newsoara Biopharma license deal. Research and development costs jumped to $9.0 million from $2.8 million a year ago, mostly as vTv kept supporting CATT1.
vTv chairman, president and CEO Paul Sekhri said the company was “executing with focus and discipline” and called the balance sheet strong enough to get the program to the next readout. GlobeNewswire
Cadisegliatin, a glucokinase activator, is designed to help the liver process glucose. As an “adjunctive” therapy, it is meant for use with insulin, not as a replacement. vTv says the CATT1 trial is looking at cadisegliatin versus placebo in around 150 adults with type 1 diabetes over six months. The main focus is on episodes of hypoglycemia, or low blood sugar. vTv Therapeutics Inc.
Dr. Klara Klein, assistant professor of medicine at UNC Chapel Hill, said last year in a company statement that people with type 1 diabetes still “walk a tightrope” with blood sugar swings and called the need for better treatments “huge.” vTv Therapeutics Inc.
Lexicon Pharmaceuticals is probably the closest public comp, as it’s been developing an insulin add-on for type 1 diabetes too. Back in September, Reuters said the FDA told Lexicon it would take longer to review the company’s extra data. The FDA had flagged concerns about diabetic ketoacidosis, which is when acids build up dangerously in the blood.
But the risk is clear. vTv shares could fall if enrollment drops, the trial fails its main endpoint, or regulators ask for extra safety info. The company says cadisegliatin is still being studied, safety and efficacy aren’t proven, and there’s no promise of approval or launch.
The stock is moving with trial timelines right now, not new developments from the company. The company’s next stated milestone is to finish CATT1 enrollment in the third quarter. After that, investors are watching for topline data from the late-stage study — the first look at the trial’s main results.
